<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:05:20 -0700</creation_date>
  <update_date>2013-01-15 19:05:20 -0700</update_date>
  <accession>HMDBP02444</accession>
  <secondary_accessions>
    <accession>7938</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>D-OR-1</synonym>
    <synonym>DOR-1</synonym>
  </synonyms>
  <gene_name>OPRD1</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Highly stereoselective. receptor for enkephalins</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04999</accession>
      <name>Loperamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04995</accession>
      <name>Codeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14339</accession>
      <name>Tramadol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14440</accession>
      <name>Morphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14477</accession>
      <name>Methadone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14640</accession>
      <name>Oxycodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14749</accession>
      <name>Butorphanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14785</accession>
      <name>Propoxyphene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14842</accession>
      <name>Naltrexone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14846</accession>
      <name>Sufentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14951</accession>
      <name>Fentanyl</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14982</accession>
      <name>Nalbuphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14992</accession>
      <name>Levorphanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15036</accession>
      <name>Remifentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15091</accession>
      <name>Hydrocodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15213</accession>
      <name>Diphenoxylate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15314</accession>
      <name>Naloxone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15323</accession>
      <name>Oxymorphone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15631</accession>
      <name>Alvimopan</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peptide receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peptide receptor activity, g-protein coupled</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>opioid receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>delta-opioid receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>1p36.1-p34.3</locus>
    <gene_sequence>&gt;1119 bp
ATGGAACCGGCCCCCTCCGCCGGCGCCGAGCTGCAGCCCCCGCTCTTCGCCAACGCCTCG
GACGCCTACCCTAGCGCCTTCCCCAGCGCTGGCGCCAATGCGTCGGGGCCGCCAGGCGCG
CGGAGCGCCTCGTCCCTCGCCCTGGCAATCGCCATCACCGCGCTCTACTCGGCCGTGTGC
GCCGTGGGGCTGCTGGGCAACGTGCTTGTCATGTTCGGCATCGTCCGGTACACTAAGATG
AAGACGGCCACCAACATCTACATCTTCAACCTGGCCTTAGCCGATGCGCTGGCCACCAGC
ACGCTGCCTTTCCAGAGTGCCAAGTACCTGATGGAGACGTGGCCCTTCGGCGAGCTGCTC
TGCAAGGCTGTGCTCTCCATCGACTACTACAATATGTTCACCAGCATCTTCACGCTCACC
ATGATGAGTGTTGACCGCTACATCGCTGTCTGCCACCCTGTCAAGGCCCTGGACTTCCGC
ACGCCTGCCAAGGCCAAGCTGATCAACATCTGTATCTGGGTCCTGGCCTCAGGCGTTGGC
GTGCCCATCATGGTCATGGCTGTGACCCGTCCCCGGGACGGGGCAGTGGTGTGCATGCTC
CAGTTCCCCAGCCCCAGCTGGTACTGGGACACGGTGACCAAGATCTGCGTGTTCCTCTTC
GCCTTCGTGGTGCCCATCCTCATCATCACCGTGTGCTATGGCCTCATGCTGCTGCGCCTG
CGCAGTGTGCGCCTGCTGTCGGGCTCCAAGGAGAAGGACCGCAGCCTGCGGCGCATCACG
CGCATGGTGCTGGTGGTTGTGGGCGCCTTCGTGGTGTGTTGGGCGCCCATCCACATCTTC
GTCATCGTCTGGACGCTGGTGGACATCGACCGGCGCGACCCGCTGGTGGTGGCTGCGCTG
CACCTGTGCATCGCGCTGGGCTACGCCAATAGCAGCCTCAACCCCGTGCTCTACGCTTTC
CTCGACGAGAACTTCAAGCGCTGCTTCCGCCAGCTCTGCCGCAAGCCCTGCGGCCGCCCA
GACCCCAGCAGCTTCAGCCGCGCCCGCGAAGCCACGGCCCGCGAGCGTGTCACCGCCTGC
ACCCCGTCCGATGGTCCCGGCGGTGGCGCTGCCGCCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>372</residue_number>
    <molecular_weight>40412.3</molecular_weight>
    <theoretical_pi>9.17</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>46-75</region>
      <region>85-102</region>
      <region>125-144</region>
      <region>175-190</region>
      <region>216-238</region>
      <region>262-284</region>
      <region>294-310</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Delta-type opioid receptor
MEPAPSAGAELQPPLFANASDAYPSAFPSAGANASGPPGARSASSLALAIAITALYSAVC
AVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELL
CKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVG
VPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRL
RSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAAL
HLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTAC
TPSDGPGGGAAA</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P41143</uniprot_id>
  <uniprot_name>OPRD_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>U07882</genbank_gene_id>
  <genecard_id>OPRD1</genecard_id>
  <geneatlas_id>OPRD1</geneatlas_id>
  <hgnc_id>HGNC:8153</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Knapp RJ, Malatynska E, Fang L, Li X, Babin E, Nguyen M, Santoro G, Varga EV, Hruby VJ, Roeske WR, et al.: Identification of a human delta opioid receptor: cloning and expression.  Life Sci. 1994;54(25):PL463-9.</reference_text>
      <pubmed_id>8201839</pubmed_id>
    </reference>
    <reference>
      <reference_text>Simonin F, Befort K, Gaveriaux-Ruff C, Matthes H, Nappey V, Lannes B, Micheletti G, Kieffer B: The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol Pharmacol. 1994 Dec;46(6):1015-21.</reference_text>
      <pubmed_id>7808419</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1.  Nature. 2006 May 18;441(7091):315-21.</reference_text>
      <pubmed_id>16710414</pubmed_id>
    </reference>
    <reference>
      <reference_text>Whistler JL, Enquist J, Marley A, Fong J, Gladher F, Tsuruda P, Murray SR, Von Zastrow M: Modulation of postendocytic sorting of G protein-coupled receptors.  Science. 2002 Jul 26;297(5581):615-20.</reference_text>
      <pubmed_id>12142540</pubmed_id>
    </reference>
    <reference>
      <reference_text>Simonin F, Karcher P, Boeuf JJ, Matifas A, Kieffer BL: Identification of a novel family of G protein-coupled receptor associated sorting proteins. J Neurochem. 2004 May;89(3):766-75.</reference_text>
      <pubmed_id>15086532</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gelernter J, Kranzler HR: Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Hum Genet. 2000 Jul;107(1):86-8.</reference_text>
      <pubmed_id>10982041</pubmed_id>
    </reference>
    <reference>
      <reference_text>Decaillot FM, Befort K, Filliol D, Yue S, Walker P, Kieffer BL: Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nat Struct Biol. 2003 Aug;10(8):629-36.</reference_text>
      <pubmed_id>12847517</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Ortiz MI, Castro-Olguin J, Pena-Samaniego N, Castaneda-Hernandez G: Probable activation of the opioid receptor-nitric oxide-cyclic GMP-K+ channels pathway by codeine. Pharmacol Biochem Behav. 2005 Dec;82(4):695-703. Epub 2006 Jan 4.</reference_text>
        <pubmed_id>16386786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9.</reference_text>
        <pubmed_id>7885194</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Loghin F, Popa DS, Socaciu C: Influence of glutethimide on rat brain mononucleotides by sub-chronic codeine treatment. J Cell Mol Med. 2001 Oct-Dec;5(4):409-16.</reference_text>
        <pubmed_id>12067475</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Advenier C, Girard V, Naline E, Vilain P, Emonds-Alt X: Antitussive effect of SR 48968, a non-peptide tachykinin NK2 receptor antagonist.  Eur J Pharmacol. 1993 Nov 30;250(1):169-71.</reference_text>
        <pubmed_id>8119316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Karlsson JA, Lanner AS, Persson CG: Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs. J Pharmacol Exp Ther. 1990 Feb;252(2):863-8.</reference_text>
        <pubmed_id>2156065</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM: Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.</reference_text>
        <pubmed_id>19027293</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10.</reference_text>
        <pubmed_id>16530171</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Dortch-Carnes J, Russell KR: Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology. 2006;77(1):17-24. Epub 2006 Mar 13.</reference_text>
        <pubmed_id>16534251</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Koch T, Wu DF, Yang LQ, Brandenburg LO, Hollt V: Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. J Neurochem. 2006 Apr;97(2):365-72. Epub 2006 Mar 15.</reference_text>
        <pubmed_id>16539674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C: Signaling pathway of morphine induced acute thermal hyperalgesia in mice.  Pain. 2006 Aug;123(3):294-305. Epub 2006 May 2.</reference_text>
        <pubmed_id>16650582</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Asensio VJ, Miralles A, Garcia-Sevilla JA: Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56. Epub 2006 Apr 6.</reference_text>
        <pubmed_id>16678156</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout.  Prog Neurobiol. 2002 Apr;66(5):285-306.</reference_text>
        <pubmed_id>12015197</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Gross ER, Hsu AK, Gross GJ: Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009 Nov;109(5):1395-402.</reference_text>
        <pubmed_id>19843777</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxycodone</name>
        <accession>HMDB14640</accession>
      </metabolite>
      <reference>
        <reference_text>Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review.  Clin Transl Oncol. 2007 May;9(5):298-307.</reference_text>
        <pubmed_id>17525040</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxycodone</name>
        <accession>HMDB14640</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60.</reference_text>
        <pubmed_id>12127012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90.</reference_text>
        <pubmed_id>12470863</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8.</reference_text>
        <pubmed_id>15942128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.</reference_text>
        <pubmed_id>8968334</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85.</reference_text>
        <pubmed_id>8746803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50.</reference_text>
        <pubmed_id>7705457</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2.</reference_text>
        <pubmed_id>17909753</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butorphanol</name>
        <accession>HMDB14749</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9.</reference_text>
        <pubmed_id>6151117</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Roy S, Guo X, Kelschenbach J, Liu Y, Loh HH: In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci. 2005 Mar 23;25(12):3229-33.</reference_text>
        <pubmed_id>15788780</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption].  Rev Neurol. 2007 Aug 1-15;45(3):155-62.</reference_text>
        <pubmed_id>17661275</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9.</reference_text>
        <pubmed_id>17487229</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Herz A: Opioid reward mechanisms: a key role in drug abuse?  Can J Physiol Pharmacol. 1998 Mar;76(3):252-8.</reference_text>
        <pubmed_id>9673788</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Herz A: Endogenous opioid systems and alcohol addiction.  Psychopharmacology (Berl). 1997 Jan;129(2):99-111.</reference_text>
        <pubmed_id>9040115</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Freye E, Latasch L, Portoghese PS: The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992 Nov;9(6):457-62.</reference_text>
        <pubmed_id>1330549</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202.</reference_text>
        <pubmed_id>8612823</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18.</reference_text>
        <pubmed_id>15665994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat.  Wound Repair Regen. 2005 Mar-Apr;13(2):165-74.</reference_text>
        <pubmed_id>15828941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200.</reference_text>
        <pubmed_id>15868528</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86.</reference_text>
        <pubmed_id>16372825</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14.</reference_text>
        <pubmed_id>16861092</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. Epub 2009 Apr 29.</reference_text>
        <pubmed_id>19403616</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB: The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52(4):389-96.</reference_text>
        <pubmed_id>8093631</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>De Souza EB, Schmidt WK, Kuhar MJ: Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.</reference_text>
        <pubmed_id>2826773</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nalbuphine</name>
        <accession>HMDB14982</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levorphanol</name>
        <accession>HMDB14992</accession>
      </metabolite>
      <reference>
        <reference_text>Prommer E: Levorphanol: the forgotten opioid.  Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13.</reference_text>
        <pubmed_id>17039381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Stucke AG, Zuperku EJ, Sanchez A, Tonkovic-Capin M, Tonkovic-Capin V, Mustapic S, Stuth EA: Opioid receptors on bulbospinal respiratory neurons are not activated during neuronal depression by clinically relevant opioid concentrations. J Neurophysiol. 2008 Nov;100(5):2878-88. Epub 2008 Sep 24.</reference_text>
        <pubmed_id>18815346</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18.</reference_text>
        <pubmed_id>15665994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat.  Wound Repair Regen. 2005 Mar-Apr;13(2):165-74.</reference_text>
        <pubmed_id>15828941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200.</reference_text>
        <pubmed_id>15868528</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86.</reference_text>
        <pubmed_id>16372825</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Remifentanil</name>
        <accession>HMDB15036</accession>
      </metabolite>
      <reference>
        <reference_text>Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14.</reference_text>
        <pubmed_id>16861092</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16.</reference_text>
        <pubmed_id>16291875</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4.</reference_text>
        <pubmed_id>14600248</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenoxylate</name>
        <accession>HMDB15213</accession>
      </metabolite>
      <reference>
        <reference_text>Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6.</reference_text>
        <pubmed_id>8583364</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Moncada A, Cendan CM, Baeyens JM, Del Pozo E: Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice. Eur J Pharmacol. 2003 Mar 28;465(1-2):53-60.</reference_text>
        <pubmed_id>12650833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Kakinohana M, Marsala M, Carter C, Davison JK, Yaksh TL: Neuraxial morphine may trigger transient motor dysfunction after a noninjurious interval of spinal cord ischemia: a clinical and experimental study. Anesthesiology. 2003 Apr;98(4):862-70.</reference_text>
        <pubmed_id>12657847</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Breljak D, Boranic M, Horvat S: Oligopeptide fragments of the enkephalin molecule interfere with hematopoietic cell colony formation. Int J Immunopathol Pharmacol. 2000 Jan-Apr;13(1):13-19.</reference_text>
        <pubmed_id>12749773</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Chudapongse N, Kim SY, Kramer RE, Ho IK: Nonspecific effects of the selective kappa-opioid receptor agonist U-50,488H on dopamine uptake and release in PC12 cells. J Pharmacol Sci. 2003 Nov;93(3):372-5.</reference_text>
        <pubmed_id>14646257</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Osman AM, Gomma M, Saad AH: A possible role for an enkephalinergic system in the internal defense mechanism of Biomphalaria alexandrina exposed to Schistosoma mansoni. J Egypt Soc Parasitol. 2003 Dec;33(3):841-61.</reference_text>
        <pubmed_id>14708857</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35.</reference_text>
        <pubmed_id>18354714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>van Dorp EL, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits.  Expert Opin Drug Saf. 2007 Mar;6(2):125-32.</reference_text>
        <pubmed_id>17367258</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management.  Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26.</reference_text>
        <pubmed_id>17595308</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ: Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.</reference_text>
        <pubmed_id>14998329</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>Neary P, Delaney CP: Alvimopan.  Expert Opin Investig Drugs. 2005 Apr;14(4):479-88.</reference_text>
        <pubmed_id>15882122</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alvimopan</name>
        <accession>HMDB15631</accession>
      </metabolite>
      <reference>
        <reference_text>Beattie DT, Cheruvu M, Mai N, O'Keefe M, Johnson-Rabidoux S, Peterson C, Kaufman E, Vickery R: The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. Epub 2007 Mar 6.</reference_text>
        <pubmed_id>17340127</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
